NCT01797081

BOTOX® in the Treatment of Crow's Feet Lines in Japan

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 20 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).

Conditions

• Lateral Canthus Rhytides
• Crow's Feet Lines

Interventions

Type	Name	Description
BIOLOGICAL	botulinum toxin Type A (24 U)	24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
BIOLOGICAL	botulinum toxin Type A (12 U)	12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
OTHER	Normal Saline	Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.

Timeline

• Start date: 2013-01-31
• Primary completion: 2013-07-18
• Completion: 2014-07-07
• First posted: 2013-02-22
• Last updated: 2019-04-16
• Results posted: 2015-02-10

Locations

1 site across 1 country: Japan